Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 10/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | MMP8 | P22894 | 2/20 | 0.30 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16019308 | 1.00 | PDK2 (0.34) | PDK2MAPTKDM4EHIF1AHSD17B10 | |
| SCHEMBL22402534 | 0.92 | PDK2 (0.37) | PDK2PTPN11MMP2MMP9MMP8 | |
| SCHEMBL5354304 | 0.92 | PDK2 (0.37) | PDK2PTPN11MMP2MMP9MMP8 | |
| SCHEMBL25444633 | 0.92 | PDK2 (0.37) | PDK2PTPN11MMP2MMP9MMP8 | |
| SCHEMBL25444635 | 0.92 | PDK2 (0.37) | PDK2PTPN11MMP2MMP9MMP8 | |
| SCHEMBL14191692 | 0.92 | ALDH1A1 (0.34) | PDK2MAPTKDM4EHSD17B10MEN1 | |
| SCHEMBL22402512 | 0.91 | PDK2 (0.37) | PDK2PTPN11MMP2MMP9MMP8 | |
| SCHEMBL25444697 | 0.91 | PDK2 (0.37) | PDK2PTPN11 | |
| SCHEMBL16544438 | 0.91 | PDK2 (0.34) | PDK2MAPTKDM4EHIF1AHSD17B10 | |
| SCHEMBL5527019 | 0.91 | PDK2 (0.37) | PDK2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039657-A1 | DETECTION METHOD | UNIV QUEENSLAND (AU) | 2023-02-09 | — | — | US | disclosed |
| US-20200284728-A1 | DETECTION METHOD | THE UNIVERSITY OF QUEENSLAND (AU) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039657-A1 | DETECTION METHOD | OPRK1, OPRM1, SIGMAR1 | PDK2 3509/4885MAPT 1302/4885KDM4E 4142/4885 |
| US-20200284728-A1 | DETECTION METHOD | OPRK1, OPRM1, SIGMAR1 | PDK2 3509/4885MAPT 1302/4885KDM4E 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.